Compare · FMS vs LSTA
FMS vs LSTA
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.72B, about 440.0x LSTA ($28.9M).
- Over the past year, FMS is down 9.1% and LSTA is up 31.6% - LSTA leads by 40.7 points.
- LSTA has been more active in the news (2 items in the past 4 weeks vs 1 for FMS).
- FMS has more recent analyst coverage (21 ratings vs 0 for LSTA).
- Company
- Fresenius Medical Care AG
- Lisata Therapeutics Inc.
- Price
- $22.76+0.02%
- $3.21-3.89%
- Market cap
- $12.72B
- $28.9M
- 1M return
- +2.18%
- -36.12%
- 1Y return
- -9.14%
- +31.56%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 2
- Recent ratings
- 21
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 3 filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form IRANNOTICE filed by Fresenius Medical Care AG
- SEC Form 20-F filed by Fresenius Medical Care AG
- Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by Goldman
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned
Latest LSTA
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 8-K filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 10-K filed by Lisata Therapeutics Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement